CoChat

Novel Glutamatergic Treatments for Severe Mood Disorders

Open access
Park, Minkyung, Niciu, Mark J., Zarate, Carlos A. · 2015 · Current Behavioral Neuroscience Reports
Cited by 40

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

All currently approved antidepressant medications for major depressive disorder (MDD) and bipolar disorder act primarily on the monoaminergic system and have varying affinities for serotonergic, norepinephrine-ergic, and/or dopaminergic receptors. Unfortunately, these drugs are only effective in approximately two thirds of patients. Glutamate is the major excitatory neurotransmitter in the central nervous system, and the glutamatergic system has been implicated in the pathophysiology of MDD. Here, we review the putative involvement of the glutamate receptor subtypes—N-methyl-d-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA), kainate, and the group I, II, and III metabotropic glutamate receptors (mGluRs)—in the development of novel and more effective treatments for mood disorders as well as preclinical and clinical trials of drugs targeting these receptors. The rapid and robust antidepressant effects of ketamine—an NMDA receptor antagonist—have been consistently replicated in multiple trials. Other glutamatergic drugs have been investigated with varying success. Here, we highlight some of the most interesting results, including the following: (1) repeated oral, intramuscular, and sublingual ketamine appears to be less robustly effective than intravenous ketamine, but also causes fewer significant adverse effects; (2) the glycine partial agonist GLYX-13 appears to be effective both as monotherapy and adjunctive treatment in the treatment of MDD. An oral analogue, NRX-1074, is currently under investigation; and (3) mGluR modulators targeting mGluR5 have demonstrated convincing preclinical results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40473-015-0050-5

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 40

Metadata

Authors
Park, M., Niciu, M. J., & Zarate, C. A.
Venue
Current Behavioral Neuroscience Reports
Published
2015-10-09
Volume
2
Issue
4
Pages
198-208
ISSN
2196-2979 (ISSN-L)
OpenAlex
W1827940801
Cited by
40
References
32
FWCI
3.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Glutamatergic Treatments for Severe Mood Disorders. https://app.cochat.ai/papers/10.1007/s40473-015-0050-5
The paper
Park, M., Niciu, M. J., & Zarate, C. A. (2015). Novel Glutamatergic Treatments for Severe Mood Disorders. Current Behavioral Neuroscience Reports. https://doi.org/10.1007/s40473-015-0050-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.